KenTakeshitaMD

Physician

Dr. Takeshita is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988
Yale-New Haven Medical CenterResidency, Internal Medicine, 1984 - 1986
Yale School of MedicineClass of 1983

PubMed

38 citations
Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
Shinsuke Iida, Takaaki Chou, Shinichiro Okamoto, Hirokazu Nagai, Kiyohiko Hatake
International Journal of Hematology. 2010-06-18
204 citations
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Thomas E. Witzig, Peter H. Wiernik, Timothy E. Moore, Craig B. Reeder, Craig Cole
Journal of Clinical Oncology. 2009-11-10
14 citations
Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.
Hironori Harada, Mitsumasa Watanabe, Kenshi Suzuki, Soshi Yanagita, Takahiro Suzuki
International Journal of Hematology. 2009-08-25

Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerDecember 9th, 2024
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. For Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerDecember 9th, 2024
Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers at ESMO Asia, SABCS and ASHDecember 2nd, 2024
Join now to see all